Table Graph
   

ivermectin - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.61 [0.20, 1.88]< 10%3 studies (3/-)80.7 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.53 [0.15, 1.95]< 10%1 study (1/-)82.8 %NAnot evaluable important-
clinical improvement (7-day) 0.90 [0.77, 1.06]> 10%1 study (1/-)9.7 %NAnot evaluable important-
death or ventilation 0.89 [0.30, 2.64]< 10%1 study (1/-)58.4 %NAnot evaluable important-
hospital discharge 1.25 [0.80, 1.95]> 10%3 studies (3/-)83.7 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.32 [0.02, 4.80]< 10%2 studies (2/-)79.5 %some concernnot evaluable moderateimportant-
viral clearance 0.93 [0.78, 1.10]> 10%2 studies (2/-)19.3 %lownot evaluable highimportant-
viral clearance (time to event analysis only) 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %NAnot evaluable important-
viral clearance by day 14 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %NAnot evaluable important-
viral clearance by day 7 0.92 [0.78, 1.08]> 10%3 studies (3/-)15.4 %lownot evaluable highimportant-
ICU admission 0.90 [0.30, 2.70]< 10%1 study (1/-)57.4 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.52 [0.01, 26.47]< 10%1 study (1/-)62.6 %NAnot evaluable important-
adverse events 1.17 [0.49, 2.78]< 10%2 studies (2/-)36.0 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons